A phase I/II study of targeted radiotherapy using holmium-166-DOTMP with melphalan and peripheral blood stem cell transplantation for treatment of multiple myeloma

Trial Profile

A phase I/II study of targeted radiotherapy using holmium-166-DOTMP with melphalan and peripheral blood stem cell transplantation for treatment of multiple myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2010

At a glance

  • Drugs Holmium-166-DOTMP (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top